Samsung Biologics Co Ltd
KRX:207940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Samsung Biologics Co Ltd
KRX:207940
|
KR |
|
Vericel Corp
NASDAQ:VCEL
|
US |
|
P
|
PICC Property and Casualty Co Ltd
OTC:PPCCY
|
CN |
|
D
|
Directa SIM SpA
F:ZP7
|
IT |
|
M&T Bank Corp
NYSE:MTB
|
US |
|
Nutrien Ltd
TSX:NTR
|
CA |
|
A
|
Amgen Inc
XMUN:AMG
|
US |
|
S
|
Sankyu Inc
TSE:9065
|
JP |
|
New China Life Insurance Co Ltd
F:NCL
|
CN |
|
M
|
Mondi PLC
SWB:KYC
|
UK |
|
U-Haul Holding Co
F:AUK0
|
US |
|
O
|
Oneflow AB
STO:ONEF
|
SE |
|
Roper Technologies Inc
SIX:ROP
|
US |
|
B
|
Barclays PLC
F:BCY
|
UK |
|
N
|
Nampak Ltd
JSE:NPK
|
ZA |
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
2
|
2G Energy AG
SWB:2GB
|
DE |
|
Goertek Inc
SZSE:002241
|
CN |
|
China Resources Mixc Lifestyle Services Ltd
HKEX:1209
|
CN |
|
Regal Rexnord Corp
NYSE:RRX
|
US |
|
UCapital24 SpA
MIL:U24
|
IT |
|
Farmers National Banc Corp
NASDAQ:FMNB
|
US |
|
G
|
Globant SA
F:2G2
|
LU |
|
Riber SA
PAR:ALRIB
|
FR |
Wall St Price Targets
Price Targets Summary
Samsung Biologics Co Ltd
According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 2 224 987.2758 KRW with a low forecast of 1 919 000 KRW and a high forecast of 2 489 550 KRW.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Samsung Biologics Co Ltd's stock price target?
Price Target
2 224 987.2758
KRW
According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 2 224 987.2758 KRW with a low forecast of 1 919 000 KRW and a high forecast of 2 489 550 KRW.
What is the Revenue forecast for Samsung Biologics Co Ltd?
Projected CAGR
13%
Over the last 11 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 7 years is 13%.
What is the Operating Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
14%
The compound annual growth rate for Operating Income over the next 7 years is 14%.
What is the Net Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
12%
The compound annual growth rate for Net Income over the next 3 years is 12%.
